Anonymous ID: 134e89 May 30, 2018, 6:53 a.m. No.1586314   🗄️.is 🔗kun

>>1586272

 

RELATED:

 

https://www.knoxnews.com/story/news/2018/05/29/cancer-cure-used-treat-myeloid-leukemia-found-oak-ridge-national-lab/636292002/

 

An ORNL isotope is saving the lives of cancer patients in medical trials, and is on its way to helping more Americans as the president prepares to sign new legislation that would allow more patients to try experimental medical treatments.

 

Actinium-225, an isotope of the element actinium, which is usually found in uranium ores, is proving effective in curing - not just treating - myeloid leukemia.

 

Myeloid leukemia

Myeloid leukemia is a rare and rapidly progressing blood and bone marrow cancer that interferes with the body's production of platelets and normal white and red blood cells.

 

The cancer is treatable in young patients, but often fatal for people over 60 years of age. That's particularly problematic because the American Cancer Society says 67 is the average age of diagnosis.

 

 

But in medical trials, Actinium-225 successfully treated the disease in elderly patients. ORNL nuclear medical scientist Saed Mirzadeh said some patients went into remission after only one treatment.

 

The isotope, when combined with tumor-seeking antibodies, is able to target and kill cancer cells without affecting healthy cells that surround them.

 

"It works very well actually; everyone is surprised how well this works compared with the other isotopes," Mirzadeh said.

 

"With leukemia, if even one percent of the leukemic cells are not killed, then there's a possibility that they come back, but for some people, the cells are all being killed in apparently just one treatment. Some had to go and get maybe the second or third treatment."

 

Trash to treasure

Mirzadeh came to ORNL from Iran in 1995. He had researched Actinium-225 for years before he came to the United States seeking bomb-grade uranium from which to extract the miracle isotope.

 

Actinium is a byproduct of Uranium-233, which the United States produced for ORNL's Molten Salt Reactor Experiment in the 1960s.

 

More: How using molten salt to cool nuclear reactors is gaining momentum in the Southeast

 

More: Contaminated Molten Salt Reactor Experiment may be entombed in concrete

 

"There is not much use for it now," Mirzadeh said. "I was naive and thought I could go and get all the U-233 and process Actinium out of it, but it turns out it was more complicated than that."

 

Then, he found out there might be another way. "They had dumped all the waste associated with the U-233 production into a stainless steel tank that was here, and that thing sat there for about 30 years," he recalled.

 

So in the late 1990s, Mirzadeh and the team of scientists he works with made a pitch to clean the waste tank and purify the Actinium inside.

 

Scientists continue to purify actinium, working in "hot," or radioactive, caves at ORNL's Radiochemical Engineering Development Center.

 

A manipulator works inside a radioactive hot cell

 

More: Oak Ridge heavy element production site receives historic designation

 

More: Inside the Radiochemical Engineering Development Center at ORNL

 

Right now, Oak Ridge is the world's only source for the isotope.

 

The project has garnered support from the Department of Energy. Mirzadeh said DOE has set a significant amount of funding aside to find another way to produce actinium if the FDA approves it as a cancer treatment.

 

Other cancers

 

Cf-252 Program Manager Julie Ezold points out a lab at the Radiochemical Engineering Development Center at Oak Ridge National Laboratory in Oak Ridge, Tennessee on Wednesday, May 16, 2018. The REDC is a multipurpose radiochemical processing and research facility which includes labs and heavily shielded hot cells used to research and develop unique radionuclides for use in research, defense, medical, and industrial applications.

 

The treatment is in the second phase of its clinical trials on human subjects, but has not yet been approved by the FDA. After this phase, it has one more to go through before the FDA will determine if it can be released to the market.

 

But, Mirzadeh and other researchers expect Actinium-225 will be released in Europe before it hits the United States market.

 

Using Actinium to cure myeloid leukemia is the only clinical trial for the isotope in the United States now, but multiple trials are going on in Europe where they have found the isotope is also effective in treating prostate cancer and brain tumors.

 

"For prostate cancer, it's actually very effective, Mirzadeh said. "They see drastic improvement compared to other isotopes and for the brain tumor, it is the same thing."